Polymerase Chain Reaction Market Size, Share & Trends Report

Polymerase Chain Reaction Market Size, Share & Trends Analysis Report By Type, By Product (Instruments, Consumables & Reagents), By Application, By Region, And Segment Forecasts, 2021 - 2028

  • Published Date: Sep, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-4-68039-188-0
  • Format: Electronic (PDF)
  • Historical Data: 2017 - 2019
  • Number of Pages: 170

Report Overview 

The global polymerase chain reaction market size was valued at USD 23.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 0.9% from 2021 to 2028. Some of the major factors propelling the Polymerase Chain Reaction (PCR) market are prenatal genetic testing procedures, increasing demand for advanced diagnostic techniques, and a rising number of CROs, forensic and research laboratories owing to their automation, real-time quantification, precision, accuracy, and sensitivity.

U.S. PCR market size, by product, 2018 - 2028 (USD Billion) 

The global SARS-CoV-2 pandemic has increased the need for reliable and rapid detection systems, such as qPCR. It is the gold standard for detecting the novel coronavirus, owing to its higher specificity and sensitivity than other tests. The development of RT-qPCR kits that can detect SARS-CoV-2, coupled with their wide acceptance globally, is a major factor likely to fuel the market. For instance, RT-PCR diagnostic panel CDC 2019-Novel Coronavirus (2019-nCoV) was approved in June 2020 by the FDA for diagnosis of the novel coronavirus. 

The combination of digital PCR and group testing methods is anticipated to reduce costs and boost the capacity of testing. For instance, the COVID-19 test by Stilla Technologies offers group testing, which reduces reagent use and improves efficiency. This new development allows users to reduce the utilization of select reagents by 80% without hampering the efficiency of the method. This improvement is anticipated to boost the demand for dPCR, as several manufacturers are facing reagent scarcity for qPCR owing to the high demand for SARS-CoV-2 testing globally.

Respiratory infection molecular diagnostics has seen an exponential demand post the spread of SARS-CoV-2 infection. In addition, the increasing number of product launches in this segment is also driving the market. For instance, in April 2020, BD announced the launch of the SARS-CoV-2 test on its BD MAX System. Increased rate of automation along with the ability to process a higher number of samples is expected to drive the demand for molecular diagnostics reagents and consumables, accelerating the market growth.

Acquisition of companies for portfolio expansion in the instruments segment is becoming a key strategy being adopted by major players. For instance, in April 2021, Hologic, Inc. announced the acquisition of Mobidiag for USD 795 million. This initiative is in line with the infectious disease PCR tests portfolio expansion strategy of Roche, ensuring continuous revenue generation in the coming years, as well as improving patient care.

Type Insights

The others segment dominated the market and accounted for the largest revenue share of more than 95.0% in 2020. The segment includes Real-time PCR (qPCR) and digital PCR, which dominated the overall market in 2020 due to increased adoption and wide applications in research. Furthermore, RT-PCR has the ability to detect PCR amplification in the early phases of reaction as compared to conventional PCR. Moreover, rapid technological advancements and increasing demand for automated systems and point-of-care diagnostics are some of the factors contributing to the growth of others segment.

In addition, the development and launch of new technologies in this segment are expected to propel the market over the forecast period. This includes plasmonic PCR, a low-cost solution that can detect pathogens and infections faster than existing PCR technologies. As per ACS Nano Journal in May 2021, plasmofluidic chips are effective and ultrafast, which can perform a PCR test in 8 minutes, and thus is expected to aid faster diagnosis in current as well as future pandemics.

Product Insights

The consumables and reagents segment dominated the market and accounted for the largest revenue share of more than 69.0% in 2020. This growth is attributable to a substantial demand for testing supplies for the SARS-CoV-2 pandemic and the increased availability of technologically advanced diagnostic equipment in countries with unmet clinical needs. In addition, the launch of new products is likely to contribute to the growth of the segment. For instance, in March 2021, PCR Biosystems announced the launch of its IsoFast Bst Polymerase reagents that support sensitive, robust, and rapid amplification of RNA and DNA, which enables faster testing procedures.

The technology is improving and is shifting toward easy-to-use products. For instance, MatMaCorp’s handheld PCR device MYRTA was launched in May 2021 facilitating real-time detection. A new entrant diagnostic system in the segment is the QuantStudio 5 Dx RT-PCR system, which was introduced by Thermo Fisher Scientific in March 2021 for laboratory use as well as assay development. The launch of the system was aimed at meeting the rising demand for PCR systems globally. In addition, the cost-effectiveness and easy-to-use interface of the system is anticipated to fuel segment growth.

Various instruments include QuantStudio 3D dPCR System and CFX96 by Bio-Rad Laboratories, Inc.; QuantStudio 3 and 5 Real-Time PCR Systems and 7500 Fast and 7500 Real-Time PCR System by Thermo Fisher Scientific, Inc.; Rotor-Gene Q by QIAGEN; LightCycler 2.0, Light Cycler 480, and Cobas 4800 by Roche Molecular Systems, Inc, and SmartCycler by Cepheid. The advantages offered by these instruments include automation, sensitivity, and specificity during the development of point-of-care diagnostics.

Application Insights

The medical segment dominated the market and accounted for the largest revenue share of 95.9% in 2020. The segment is anticipated to maintain its dominance over the forecast period due to its advantages in research and other applications, such as detecting and quantifying low-frequency mutations and low levels of pathogens with higher sensitivity. Moreover, increasing adoption in diagnostic centers and hospitals is propelling the growth of the segment.

Global PCR market share, by application, 2020 (%)

Researchers are focusing on human pluripotent stem cells for the study of genomes and genomic abnormalities. According to a study in 2020, the current assays are not suitable for regular screening of hPSC genomic integrity. The development of tests for screening of hPSC recurrent genetic abnormalities is expected to contribute to the growth of the market. Furthermore, constant efforts of researchers for the development of regenerative biomedicine from Induced Pluripotent Stem Cells (iPS cells) are anticipated to boost product uptake across various geographies.

Increasing adoption of PCR for food safety and detecting infection along with food-borne pathogens and toxicogenic fungi is expected to drive the market. Species identification has become increasingly vital in some applications such as meat species identification. According to a study in 2020, a loss of around USD 45.6 million was observed in Europe due to adulterated horse meat in beef products. Several scientists are currently engaged in the development of PCR tests for species identification. The most widely used tests include species-specific PCR, Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP), probe-based TaqMan real-time PCR.

Regional Insights

North America dominated the Polymerase Chain Reaction market and accounted for the largest revenue share of 37.8% in 2020. Favorable government initiatives, coupled with flexible regulatory guidelines are anticipated to propel market growth in North America. For instance, in February 2020, the Department of Health and Human Services announced the authorization of emergency use of diagnostics for detection of COVID-19. This authorization increased the number of diagnostics product launches in the region.

In Asia Pacific, the market is estimated to grow fast over the forecast period due to improvements in healthcare infrastructure, an increase in patient awareness levels, and high unmet patient needs. The COVID-19 pandemic has put immense strain on qPCR, endpoint PCR, and dPCR diagnostics in this region, due to high incidence and densely populated areas. Nearly half of the global population resides in this region, led by China and India. The majority of the countries in Asia Pacific are on high alert due to the SARS-CoV-2 virus spread. Thus, the demand for PCR instruments and consumables is projected to be high in the region to manage the impact of the pandemic in the countries.

Key Companies & Market Share Insights

Key companies are focusing on R&D to develop advanced technology products to gain a competitive edge. Major players are engaged in mergers and acquisitions, partnerships, with an aim to strengthen their product portfolio, manufacturing capacities, and provide competitive differentiation. In January 2021, Thermo Fisher Scientific, Inc. announced the acquisition of Mesa Biotech, Inc. - a molecular diagnostic company-for USD 450 million to expand its product portfolio. Some of the prominent players in the Polymerase Chain Reaction (PCR)market include:

  • Abbott

  • Qiagen

  • Thermo Fisher Scientific, Inc.

  • Bio-Rad Laboratories, Inc.

  • bioMérieux SA

  • F. Hoffmann-La Roche Ltd

  • Agilent Technologies, Inc.

  • Fluidigm Corporation

  • Cytiva

  • Stilla Technologies

  • Microsynth AG

  • JN Medsys

  • Danaher Corporation

Polymerase Chain Reaction Market Report Scope

Report Attribute

Details

Market size value in 2021

USD 29.14 billion

Revenue forecast in 2028

USD 25.3 billion

Growth Rate

CAGR of 0.9% from 2021 to 2028

Base year for estimation

2020

Historical data

2017 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Type, product, application, and region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Spain; Italy; China; Japan; India; South Korea; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Abbott; Qiagen; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; bioMérieux SA; F. Hoffmann-La Roche Ltd.; Agilent Technologies, Inc.; Fluidigm Corporation; Cytiva; Stilla Technologies; Microsynth AG; JN Medsys; Danaher Corporation

Customization scope

Free report customization (equivalent to up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope.

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. Explore purchase options

 

Segments Covered in the Report 

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global Polymerase Chain Reaction Market report on the basis of type, product, application, and region:

  • Type Outlook (Revenue, USD Million, 2017 - 2028)

    • Conventional PCR

    • Others

  • Product Outlook (Revenue, USD Million, 2017 - 2028)

    • Consumables & Reagents

    • Instruments

    • Software & Services

  • Application Outlook (Revenue, USD Million, 2017 - 2028)

    • Medical

      • Clinical

        • Pathogen Testing

        • Oncology Testing

        • Blood Screening

        • Others

      • Research

      • Forensic and others

    • Non-Medical

      • Food

      • Others

  • Regional Outlook (Revenue, USD Million, 2017 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

    • Asia Pacific

      • China

      • India

      • Japan

      • South Korea

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.